Foster City, United States
Adela, Inc. is poised to revolutionize cancer care through its transformative blood testing technology. With the compelling slogan, "Imagine a world in which a single blood draw can be used to detect and enable early treatment of many different diseases," Adela is committed to leveraging biology to advance cancer diagnostics and treatment.
Founded in 2020, Adela stands at the forefront of innovation in the healthcare sector. The company's unique genome-wide methylation enrichment technology was pioneered by Dr. Daniel De Carvalho at the University Health Network’s Princess Margaret Cancer Centre. Initially, Adela aims to apply this technology across the cancer spectrum—from detection to disease management.
Based in the United States, Adela recently secured a $48.00M Series A investment on September 25, 2023, attracting backing from prominent investors like F-Prime Capital, RA Capital Management, OrbiMed, Decheng Capital, Deerfield Management, and LabCorp. This substantial funding underscores investor confidence in Adela's potential to make significant strides in oncology.
OncoDNA